A Systematic Review of Treatments for Relapsed/Refractory Mantle Cell Lymphoma

Publication date: Available online 13 October 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson A systematic literature review was conducted to evaluate the clinical effectiveness and safety of treatments for patients with relapsed/refractory mantle cell lymphoma (MCL) unsuitable for intensive treatment. Criteria for inclusion of trials were established prior to the literature review. A search of Medline, Embase and the Cochrane library databases was conducted to identify phase II or III randomised controlled trials (RCTs), published from January 1st 1994 to 29th May 2016. Relevant conference abstracts, citation lists from included articles, published guidelines and on-going clinical trial databases were also searched. Articles were included if they evaluated any single agent or combination of treatments in adult patients with relapsed/refractory MCL who had received at least one prior line of therapy. Seven RCTs were identified. Only one treatment appeared in more than one trial, and therefore results from each trial could not be quantitatively pooled by meta-analysis. Lack of common comparators, differences in baseline characteristics and inclusion and exclusion criteria and variance in the response criteria used to measure outcomes, made comparison of results difficult. Although the direction of effect for PFS and OS was in favour of the experimental drug in all trials, PFS was statistically si...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research